(Total Views: 587)
Posted On: 04/01/2024 6:20:52 PM
Post# of 154785
Quote:
From @Bio4 on Stocktwits. PASC discussion and LL by Drs. Blayliss and Yang
Quote:
The trial also observed significantly increased blood cell surface CCR5 from baseline to day 56 in leronlimab treated symptomatic responders but not in leronlimab treated non-responders or those participants who received placebo. To our surprise, rather that showing that PASC is mediated by persisting inflammation after acute COVID-19 we had to conclude that at least in some individuals with PASC there is an unexpected immune downmodulation prior to leronlimab treatment which was normalized after leronlimab treatment.
https://www.sciencedirect.com/science/article...532400080X
What confounds things a bit is the number of patients with few to no symptoms. They of course would be classified as non-responders mucking up the results.
Other studies have shown a rise in CD4+ T-cells and a drop in CD8+ T-cells in longhaulers patients. We know that leronlimab can balance out CD4+/CD8+ T-cell ratios. The effect in responders may be as simple as lowering inflammation and the increased CD8+ T-cells helping to eliminate viral particles.
(10)
(0)
